Ask AI

The APP Advantage: Optimizing BCMA- and GPRC5D-Directed Bispecific Antibody Care in Multiple Myeloma

Enhance your ability to apply current and emerging evidence on BCMA- and GPRC5D-directed bispecific antibody strategies to improve care for patients with relapsed/refractory multiple myeloma through a certified on-demand webcast with an AI assistant and accompanying downloadable slides.

Share

Program Content

Events

  • Live Event
    The APP Advantage: Optimizing BCMA- and GPRC5D-Directed Bispecific Antibody Care in Multiple Myeloma
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

BsAbs for MM for APPs
The APP Advantage: Optimizing BCMA- and GPRC5D-Directed Bispecific Antibody Care in Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 18, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson